AR033510A1 - Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestiva - Google Patents
Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestivaInfo
- Publication number
- AR033510A1 AR033510A1 ARP010100738A ARP010100738A AR033510A1 AR 033510 A1 AR033510 A1 AR 033510A1 AR P010100738 A ARP010100738 A AR P010100738A AR P010100738 A ARP010100738 A AR P010100738A AR 033510 A1 AR033510 A1 AR 033510A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- treatment
- fatty acids
- partial oxidation
- cardiac insufficiency
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los métodos se describen para tratar la insuficiencia cardíaca congestiva con inhibidores de oxidacion parcial de ácidos grasos. Los compuestos aumentan el rendimiento cardíaco sin afectar la frecuencia cardíaca, la presion sanguínea o el consumo de oxígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18356000P | 2000-02-18 | 2000-02-18 | |
US21990800P | 2000-07-21 | 2000-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033510A1 true AR033510A1 (es) | 2003-12-26 |
Family
ID=26879274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100738A AR033510A1 (es) | 2000-02-18 | 2001-02-19 | Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestiva |
Country Status (17)
Country | Link |
---|---|
US (2) | US6528511B2 (es) |
EP (2) | EP2033633A3 (es) |
JP (1) | JP2004505886A (es) |
KR (1) | KR20020075801A (es) |
CN (1) | CN1227004C (es) |
AR (1) | AR033510A1 (es) |
AU (1) | AU778203B2 (es) |
BR (1) | BR0108452A (es) |
CA (1) | CA2398691A1 (es) |
HK (1) | HK1048250A1 (es) |
IL (1) | IL151014A0 (es) |
MX (1) | MXPA02007639A (es) |
NO (1) | NO20023879L (es) |
NZ (1) | NZ520780A (es) |
TW (1) | TWI235655B (es) |
WO (1) | WO2001060348A2 (es) |
ZA (1) | ZA200206451B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0108452A (pt) * | 2000-02-18 | 2003-04-01 | Cv Therapeutics Inc | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva |
WO2003037323A2 (en) * | 2001-10-26 | 2003-05-08 | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie | Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction |
DE60221287T4 (de) * | 2001-11-08 | 2009-06-25 | Atrium Medical Corp. | Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
EP1505977B1 (en) * | 2002-05-21 | 2014-09-10 | Gilead Sciences, Inc. | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes |
EP1567525B1 (en) * | 2002-12-05 | 2007-06-27 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
AU2004303882A1 (en) * | 2003-12-18 | 2005-07-07 | Gilead Palo Alto, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
EP2298863B1 (en) † | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US8263102B2 (en) * | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801913B2 (en) * | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9801982B2 (en) * | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
EP1809289A1 (en) * | 2004-11-09 | 2007-07-25 | Cv Therapeutics, Inc. | Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
EP1865945A4 (en) * | 2005-03-11 | 2008-05-21 | Hong Kong Nitric Oxide Ltd | TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US7606617B2 (en) * | 2006-01-31 | 2009-10-20 | Cardiac Pacemakers, Inc. | Urinalysis for the early detection of and recovery from worsening heart failure |
US9782258B2 (en) * | 2006-09-08 | 2017-10-10 | The Regents Of The University Of California | Intramyocardial patterning for global cardiac resizing and reshaping |
US20090012413A1 (en) * | 2006-09-08 | 2009-01-08 | Sabbah Hani N | Cardiac patterning for improving diastolic function |
WO2008057328A2 (en) * | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9492596B2 (en) * | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
JP2010518169A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
AU2008239681B2 (en) * | 2007-04-11 | 2013-10-03 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
KR20100033490A (ko) * | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
CN101066253B (zh) * | 2007-06-07 | 2011-01-05 | 北京本草天源药物研究院 | 一种雷诺嗪缓释片 |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
KR20110013348A (ko) * | 2008-02-06 | 2011-02-09 | 길리애드 사이언시즈, 인코포레이티드 | 통증 치료를 위한 라놀라진의 용도 |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
WO2011036677A2 (en) * | 2009-09-25 | 2011-03-31 | Lupin Limited | Sustained release composition of ranolazine |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
ES2414384T3 (es) * | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
CN104758265B (zh) * | 2014-01-07 | 2019-05-17 | 四川海思科制药有限公司 | 一种雷诺嗪缓释片药物组合物及其制备方法 |
FR3060567B1 (fr) | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
CN112438955A (zh) * | 2019-08-30 | 2021-03-05 | 深圳翰宇药业股份有限公司 | 一种雷诺嗪缓释组合物及其制备方法 |
GR1010510B (el) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5001193A (en) | 1988-12-22 | 1991-03-19 | American Cyanamid | Epoxy adhesive for bonding of automotive parts made from bulk or sheet molding compound containing polymeric toughening agent and Mannich Base |
EP0714660B1 (en) | 1989-06-23 | 2002-09-04 | Syntex (U.S.A.) LLC | Ranolazine and related piperazines for protecting skeletal muscles |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
BR0108452A (pt) * | 2000-02-18 | 2003-04-01 | Cv Therapeutics Inc | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva |
EP1259493A2 (en) * | 2000-02-22 | 2002-11-27 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
-
2001
- 2001-02-15 BR BR0108452-6A patent/BR0108452A/pt not_active Application Discontinuation
- 2001-02-15 EP EP08018568A patent/EP2033633A3/en not_active Withdrawn
- 2001-02-15 CN CNB018051499A patent/CN1227004C/zh not_active Expired - Fee Related
- 2001-02-15 MX MXPA02007639A patent/MXPA02007639A/es active IP Right Grant
- 2001-02-15 KR KR1020027010748A patent/KR20020075801A/ko active Search and Examination
- 2001-02-15 WO PCT/US2001/004887 patent/WO2001060348A2/en not_active Application Discontinuation
- 2001-02-15 IL IL15101401A patent/IL151014A0/xx unknown
- 2001-02-15 NZ NZ520780A patent/NZ520780A/en not_active IP Right Cessation
- 2001-02-15 JP JP2001559446A patent/JP2004505886A/ja active Pending
- 2001-02-15 AU AU41505/01A patent/AU778203B2/en not_active Ceased
- 2001-02-15 CA CA002398691A patent/CA2398691A1/en not_active Abandoned
- 2001-02-15 US US09/784,559 patent/US6528511B2/en not_active Expired - Lifetime
- 2001-02-15 EP EP01912758A patent/EP1259230A2/en not_active Ceased
- 2001-02-16 TW TW090103593A patent/TWI235655B/zh not_active IP Right Cessation
- 2001-02-19 AR ARP010100738A patent/AR033510A1/es unknown
-
2002
- 2002-08-13 ZA ZA2002/06451A patent/ZA200206451B/en unknown
- 2002-08-15 NO NO20023879A patent/NO20023879L/no not_active Application Discontinuation
- 2002-08-27 US US10/228,573 patent/US6677342B2/en not_active Expired - Lifetime
-
2003
- 2003-01-20 HK HK03100016.7A patent/HK1048250A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US6677342B2 (en) | 2004-01-13 |
IL151014A0 (en) | 2003-02-12 |
CN1420766A (zh) | 2003-05-28 |
WO2001060348A3 (en) | 2002-01-31 |
AU4150501A (en) | 2001-08-27 |
US20030119718A1 (en) | 2003-06-26 |
HK1048250A1 (zh) | 2003-03-28 |
EP1259230A2 (en) | 2002-11-27 |
JP2004505886A (ja) | 2004-02-26 |
WO2001060348A2 (en) | 2001-08-23 |
NO20023879D0 (no) | 2002-08-15 |
US20010047000A1 (en) | 2001-11-29 |
EP2033633A2 (en) | 2009-03-11 |
AU778203B2 (en) | 2004-11-25 |
CN1227004C (zh) | 2005-11-16 |
TWI235655B (en) | 2005-07-11 |
NZ520780A (en) | 2006-04-28 |
CA2398691A1 (en) | 2001-08-23 |
MXPA02007639A (es) | 2004-08-23 |
US6528511B2 (en) | 2003-03-04 |
KR20020075801A (ko) | 2002-10-05 |
ZA200206451B (en) | 2003-12-31 |
NO20023879L (no) | 2002-08-15 |
EP2033633A3 (en) | 2009-07-08 |
BR0108452A (pt) | 2003-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033510A1 (es) | Inhibidores de la oxidacion parcial de acidos grasos para el tratamiento de la insuficiencia cardiaca congestiva | |
ATE304849T1 (de) | Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung | |
EA200100721A1 (ru) | Производное габапентина для предупреждения и лечения висцеральной боли | |
AR041472A1 (es) | Complejos de carbohidrato de hierro acuosos su produccion y medicamentos que los contienen | |
ECSP014055A (es) | Activadores de glucoquinasa que contienen hidantoina | |
CY1108292T1 (el) | Αντικαρκινικο σκευασμα που περιεχει dmxaa | |
CY1105915T1 (el) | Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar | |
DE60232245D1 (de) | Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen | |
EA200401398A1 (ru) | Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы | |
ATE327753T1 (de) | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes | |
UY28081A1 (es) | Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular | |
EA200401111A1 (ru) | Биполярные соли транс-каротиноидов и их применение | |
DE69840497D1 (de) | Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen | |
ES2051675T3 (es) | Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores. | |
MXPA02004598A (es) | Compuestos novedosos para tratar diabetes y condiciones asociadas. | |
EA200100852A1 (ru) | Производные резорцина | |
ATE272436T1 (de) | Mikrofiltration unter verwendung von aktivkohle | |
DE602006010691D1 (de) | Verwendung von glycerin zur verbesserung der herzfunktion | |
CL2004000512A1 (es) | Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes | |
PE108599A1 (es) | Procedimiento para la estabilizacion de acido ascorbico levogiro (laa), composicion acuosa estable de laa, procedimiento para la preparacion de una solucion topica estable de laa, emulsion y producto vitaminico que lo contiene | |
EA199900948A1 (ru) | Способ получения 2-арил-3-арил-5-галогенпиридинов, используемых в качестве ингибиторов cox-2 | |
ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
SE0200198D0 (sv) | New use | |
UY26648A1 (es) | Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada | |
RU2009106380A (ru) | Способ лечения осложненного гнойного пиелонефрита с применением раствора гипохлорита натрия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |